Cardiac toxicity: Old and new issues in anti-cancer drugs

Clinical and Translational Oncology

Volumn 10, Issue 1, 2008, Pages 35-46

  Sereno, María ^a,d   Brunello, Antonella ^b   Chiappori, Alberto ^c   Barriuso, Jorge ^a   Casado, Enrique ^a   Belda, Cristóbal ^a   Castro, Javier ^a   Feliu, Jaime ^a   González Barón, Manuel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d NONE   (Spain)

Author keywords

Cardiac toxicity; Monoclonal antibodies; Tyrosine kinase inhibitors

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ERYTHROPOIETIN; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; GONADORELIN DERIVATIVE; IMATINIB; LAPATINIB; LETROZOLE; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; ANGIOGENESIS INHIBITOR; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATINUM COMPLEX; TAXOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; ANGINA PECTORIS; ANTIANGIOGENIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; BRADYCARDIA; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHANNELOPATHY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELECTROCARDIOGRAM; ENDOCRINE DISEASE; FATIGUE; FEMALE INFERTILITY; FEVER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MYOCARDITIS; NEOPLASM; NEUTROPENIA; NONHUMAN; PAIN; PERICARDIAL EFFUSION; PERICARDITIS; PROSTATE CANCER; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL CELL CARCINOMA; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; DEOXYCYTIDINE; FLUOROURACIL; HEART DISEASES; HUMANS; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAXOIDS;

EID: 43249112054     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0150-8     Document Type: Review

References (112)

1. Corna G, Santambrogio P, Mintoti G, Cairo G (2004). Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738-13745
2. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717
3. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879
4. Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084
5. Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330-352
6. Fu P, Arcasoy MO (2007) Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun 354:372-378
7. Silber JH, Canan A, Clark BJ et al (2001) Design and baseline characteristics for the ACE inhibitor after anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. Am Heart J 142:577
8. Mayne Pharma (Canada) Inc., Doxorubicin Product Monograph. Date of revision: 2002
9. Nielsen D, Jensen JB, Dombernowsky P et al (1990) Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810
10. Ryberg M, Nielsen D, Skovsgaard T et al (1998) Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508
11. Gluck S (2005) Adjuvant chemotherapy for early breast cancer: Optimal use of epirubicin. Oncologist 10:780-791
12. Minotti G, Licata S, Saponiero A et al (2000) Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4FE-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 13:1336-1341
13. Hasinoff BB, Schanbl KL, Marusak RA et al (2003) Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3:89-99
14. Kaiserova H, den Hartoq GJ, Simunek T et al (2006) Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. Br J Pharmacol 149:920-930
15. Gabizon AA (2001) Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Investigation 19:424-436
16. Batist G, Ramakrishnan G, Rao C et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454
17. Harris L, Batist G, Belt R et al (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36
18. Chan S, Davidson N, Juozaityte E et al (1999) Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and Cyclophosphamide (CPA) vs Epirubicin and CPA in first-line treatment of metastatic breast cancer (MBC). Eur J Cancer 35:315-321.
19. Theodoulou M, Hudis C (2004) Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 100:2052-2063
20. Alberts DS, Franco M, Carmichael J et al (2004) Efficacy and safety of liposomal anthracycline in phase I/II clinical trials. Semin Oncol 32[Suppl 13]:53-90
21. Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029-1033
22. O'Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of Pegylated Liposomal Doxorubicin HC1 (Caelyx/Doxil) versus conventional Doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449
23. Andreopoulou E, Gaiotti D, Kim E et al (2007) Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 18:716-721
24. Chia S, Clemons M, Martin LA et al (2006) Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol 24:2773-2778
25. Grasselli G, Vigano L, Capri G et al (2001) Clinical and pharmacologic study of the Epirubicin and Paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19:2222-2231
26. Schrader C, Keussen C, Bewig B et al (2005) Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 10:498-501
27. Yamac D, Elmas C, Ozogul C et al (2006) Ultrastructural damage in vascular endothelium in rats treated with Paclitaxel and Doxorubicin. Ultrastruct Pathol 30:103-110
28. Salvatorelli E, Menna P, Cascegna S et al (2006) Paclitaxel and Docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of Doxorubicin-Taxane chemotherapies. J Pharmacol Exp Ther 318:424-433
29. Schuller J, Czejka M, Kletzl H et al (1998) Doxorubicin (DOX) and Taxotere (TXT). A pharmacokinetic (PK) study of the combination in advanced breast cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting 1998, Abstract #790
30. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albuminbound Paclitaxel compared with polyethylated castor oil-based Paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803
31. Bertolini, M. Flumano J, Fusco O et al (2001) Acute cardiotoxicity during capecitabine treatment: A case report. Tumori 87:200-206
32. Frickhofen N, Beck NJ, Jung B et al (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 5:797-801
33. Arbea L, Coma Canella I, Martinez-Monge R et al (2007) A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 13:2135-2137
34. Schober C, Papageorgiou E, Harstrick A et al (1993) Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72:2242-2247
35. Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487-493
36. Ferrari D, Carbone C, Codeca C et al (2006) Gemcitabine and atrial fibrillation: A rare manifestation of chemotherapy toxicity. Anticancer Drugs 17:359-361
37. Santini D, Tonini G, Abbate A et al (2000) Gemcitabine-induced atrial fibrillation: A hitherto unreported manifestation of drug toxicity. Ann Oncol 11:479-481
38. Ng M, Cunningham D, Norman AR (2005) The frequency and pattern of cardiotoxicity observed with Capecitabine used in conjunction with Oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41:1542-1546
39. De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion Fluorouracil: A prospective clinical study. J Clin Oncol 10:1795-1801
40. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442
41. BIG 1-98 Collaborative group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 355:2747-2757
42. Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of Letrozole compared with Tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492
43. Howell A, Cuzick J, Baum M et al [ATAC trialists' group] (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
44. Coombes RC, Kilburn LS, Snowdon CF et al (Intergroup Exemestane Study) (2007) Survival and safety of Exemestane versus Tamoxifen after 2-3 years' Tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570
45. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to Anastrozole after 2 years' adjuvant Tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455-462
46. Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to Anastrozole versus continued Tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 17[Suppl 7]:10-14
47. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of Letrozole following Tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
48. Coli S, Magnoni M, Melisurgo G et al (2007) Myocardial infarction complicating the initial phase of an ovarian stimulation protocol. Int J Cardiol 115:56-57
49. Keating LN, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 256:4448-4456
50. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
51. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science 304:1497-1500
52. Pao W, Miller V, Zakowsky M et al (2004) EGF receptor gene mutations are common in lung cancers form never smokers and are associated with sensitivity of tumors to Gefitinib and Erlotinib. Proc Natl Acad U S A 101:13306-13311
53. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-132
54. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: Results from a randomized, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537
55. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of Imatinib Mesylate in advanced gastrointestinal stromal tumors. N Engl Med 347:472-480
56. Francois H, Placier S, Flamant M et al (2004) Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 10:1-19
57. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 35:337-345
58. Bonner JA, Giralt J, Harari PM et al (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of the head and neck: A phase III study of high dose radiation therapy with or without Cetuximab. J Clin Oncol 22:5507
59. Saltz LB, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
60. Huang S, Li J, Harari PM (2002) Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after Epidermal growth factor receptor blockade. Mol Cancer Ther 1:507-514
61. Perrotte P, Matsumoto T, Inoue K et al (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-264
62. Pegram M, Slamon D (2000) Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27:13-19
63. Baselga J (2001) Herceptin alone or in combination with chemotherapy in the treatment of Her-2 positive metastatic breast cancer. Pivotal trials. Oncology 61:14-21
64. Ewer M, Vooletich M, Duran J et al (2005) Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 1: 7820-7826
65. Piccard-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Herceptin Adjuvant (HERA) trial Study Team. N Engl J Med 353:1659-1672
66. Keefe D (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600
67. Salmon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 344:783-792
68. Ng R, Green MD (2007) Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf 6:315-321
69. Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173-183
70. Crone SA, Zhao YY, Fan L et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:263-266
71. Ozcelik C, Erdmann B, Pilz B et al (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 99:8880-8885
72. Grazette L, Boecker W, Matsui T et al (2004) The inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes. Implications for Herceptin-induced cardiomyopathy. J Am Coll Cardiol 11:2231-2238
73. Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 31:7820-7826
74. Burris I (2004) Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9:10-15
75. Blackwell KL, Kaplan EH, Franco SX et al (2004) A phase II, open-label, multicenter study of Lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on Trastuzumab containing regimen. Ann Oncol 15:27-31
76. Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus Capecitabine for Her-2 positive advanced breast cancer. N Engl J Med 28:2733-2743
77. O'Brien SG, Guilhot F, Larson RA et al (2002) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 348:994-1004
78. Park YH, Park HJ, Kim BS et al (2006) BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 243:16-22
79. Kerkela R, Grazzette L, Yacobo R et al (2006) Cardiotoxicity of the cancer therapic agent Imatinib Mesylate. Nature Med 8:908-916
80. Sun X (2000) Activation of the cytoplasmatic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem 275:17237-17240
81. Verweij J, Casali PG, Kotasek D et al (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43:974-978
82. Mann D (2006) Targeted cancer therapeutics: The heartbreak of success. Nature Med 8:881-882
83. Shah NP, Tran C, Lee FY (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401
84. Sawyers CL, Shah NP, Kantarjian HM (2005) A phase I study of BMS-354825 in patients with Imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia: From CA 180002. J Clin Oncol 23:256-260
85. Talpaz M, Shah N, Kantarjan H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 24:2531-2541
86. Fieldler W, Serve H, Dohner H et al (2005) A phase 1 study of SU 11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 3:986-993
87. Mozter R, Hutson T, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2:115-124
88. Mozter R, Rini B, Bukowski R et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 21:2516-2524
89. Strumberg D, Richly H, Higer RA (2005) Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-971
90. Escudier B, Eisen T, Stadler W et al (2007) Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125-134
91. Gordon M, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant Human Anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
92. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II randomized trial comparing Bevacizumab plus Fluoracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
93. Hurwitz H, Ferenbacher L, Novotny W et al (2004) Bevacizumab plus Irinotecan, Fluoracil and Leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
94. Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) High dose Bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the American Society of Clinical Oncology Annual Meeting, 13-17 May 2005, Orlando, FL, Abstract 3508
95. Hochster SH, Hart LL, Ramanathan RK et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without Bevacizumab as first line treatment of metastatic colorectal cancer: Final analysis of the TREE-Study. Presented at the American Society of Clinical Oncology Annual Meeting, 2-6 June 2006, Atlanta, GA, Abstract 3510
96. Sandler A, Gray R, Perry M et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550
97. D'Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23:7135-7142
98. Eskens F, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42:3127-3139
99. Kuenen BC, Levi M, Meijers JC et al (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine and the angiogenesis inhibitor SU 5416. J Clin Oncol 21:2192-2198
100. Hambleton J, Novotny W, Hurwitz H et al (2004) Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol [Suppl]:aBstract 3528
101. Herrmann J, Ciechanover A, Lerman LO et al (2004) The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 61:11-21
102. Hiseshima T, Mitsiades C, Akiyama M et al (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534
103. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed Multiple Myeloma. N Engl J Med 352:2487-2498
104. Voortman J, Giaccone G (2006) Severe reversible cardiac failure after Bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer 11:129
105. Lenihan D, Alencar A, Yang D et al (2004) Cardiac toxicity of Alemtuzumab in patients with mycosis fungoides/Sezary Syndrome. Blood 104:655-658
106. Mavromatis B, Cheson BD (2003) Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 21:1874-1881
107. Osterborg A (2005) No cardiac toxicity associated with Alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 10:4148-4149
108. Wing MG, Moreau T, Greenwood J et al (1996) Mechanism of first dose cytokine-release syndrome by CAMPATH-1H: Involvement of CD16 (FcãRIII) and CD11a/CD11a/CD18 (LFA-1) or NK cells. J Clin Invest 98:2819-2826
109. Servitje O, Limon A, Blanco A et al (1999) Cardiac involvement and molecular staging in a fatal case of mycosis fungoides. Br J Dermatol 141:531-535
110. Ewert M, Vouletich M, Durand J et al (2005) Reversibility of trastuzumab related cardiotoxicity. New insights based on clinical course and response to medical treatment. J Clin Oncol 31:7820-7826
111. Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis and management. Circulation 109:3122-3131
112. Sugal PK, Hiskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905